Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Inovio Pharmaceuticals Inc (NASDAQ:INO)

7.88
Delayed Data
As of May 26
 -0.11 / -1.38%
Today’s Change
5.83
Today|||52-Week Range
11.62
+13.54%
Year-to-Date
Inovio (INO) Stock Rises on Encouraging HIV Vaccine Data
May 26 / Zacks.com - Paid Partner Content
Biotech Movers: Inovio, Neurocrine, Alnylam
May 24 / TheStreet.com - Paid Partner Content

Today’s Trading

Previous close7.99
Today’s open7.95
Day’s range7.84 - 8.21
Volume1,631,705
Average volume (3 months)1,132,211
Market cap$588.1M
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)-129.55%
Earnings growth (this year)--
Earnings growth (next 5 years)0.00%
Revenue growth (last year)-12.83%
P/E ratioNM
Price/Sales14.37
Price/Book4.73

Competitors

 Today’s
change
Today’s
% change
FLXNFlexion Therapeutics...-0.46-2.45%
ACHNAchillion Pharmaceut...+0.06+1.45%
ENTAEnanta Pharmaceutica...-0.23-0.76%
RETAReata Pharmaceutical...-1.17-4.15%
Data as of 3:59pm ET, 05/26/2017

Financials

Next reporting dateAugust 10, 2017
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$35.4M
Annual profit (last year)-$73.7M
Net profit margin-208.49%

Profile

Sector
Health Technology
Industry
Medical Specialties
President, Chief Executive Officer &
Director
J. Joseph Kim
Chief Operating Officer
Niranjan Y. Sardesai
Corporate headquarters
Plymouth Meeting, Pennsylvania

Forecasts